Enjoy complimentary customisation on priority with our Enterprise License!
The chronic myelogenous leukemia therapeutics market size will grow by USD 1.74 billion during 2019-2023. This market report provides a detailed analysis of the market by product (targeted therapy, chemotherapy, and immunotherapy) and geography (Asia, Europe, North America, and ROW). Also, the report analyzes the market’s competitive landscape and offers information on many market vendors, including Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Mylan NV, Novartis AG, Otsuka Holdings Co. Ltd., Pfizer Inc., Takeda Pharmaceutical Co. Ltd., and Teva Pharmaceutical Industries Ltd.
Key Insights on Chronic Myelogenous Leukemia Therapeutics Market – Global Forecast 2019-2023
Browse TOC and LoE with selected illustrations and example pages of Chronic Myelogenous Leukemia Therapeutics Market
The CML therapeutics market has witnessed a number of strategic alliances over recent years. Market vendors are focusing on collaborations to expand their distribution networks and reduce costs associated with the R&D of CML therapeutics. Collaborations among vendors are influencing market growth by increasing patient adherence by reducing the cost burden. For instance, the BMS recently collaborated with The MAX Foundation to provide free drugs to patients who are unable to access the treatment. The strategic alliances between vendors have also increased the development of diagnostic kits and testing services, which have resulted in the early diagnosis of the disease and increased adoption for the treatment. Effective alliances among companies will significantly fuel the growth of the CML therapeutics market size during 2019-2023.
Crucial chronic myelogenous leukemia therapeutics market trends such as the development of diagnostic tests and predictive markers will also influence market growth. The high unmet need is encouraging companies to research diagnostic testing methods that help in the early detection of CML. These developments include diagnostic kits in oncology to effectively monitor the molecular response of the indication at an early stage. Vendors are also introducing predictive biomarkers for CML for the intrinsic sensitivity of TKI drugs. For instance, HMGCLL1 is a predictive biomarker in CML for deep molecular response to imatinib therapy.
Similarly, microRNAs are used as biomarkers to study the progression of CML and the resistance to TKI drugs. These developments are expected to enhance the effectiveness of CML therapy drugs. As a result of these factors, the myelogenous leukemia therapeutics market will register a CAGR of nearly 6% during the forecast period.
The global market is fragmented. To help clients improve their market positions, this chronic myelogenous leukemia therapeutics market forecast report provides an analysis of the market’s competitive landscape and offers information on the products offered by various companies. This chronic myelogenous leukemia therapeutics market analysis report also includes information on the upcoming trends and challenges that will influence market growth. This will help companies create strategies to make the most of future growth opportunities.
The report offers a detailed analysis of several leading chronic myelogenous leukemia therapeutics companies, including:
The targeted therapy segment held the largest market share in 2018. It will account for the highest chronic myelogenous leukemia therapeutics market share over the forecast period as well. The market is witnessing an increase in the number of approved TKI drugs for the treatment of chronic phase CML. The increasing number of approvals for orphan drug destinations is also fueling the growth of the segment. This report provides an accurate prediction of the contribution of all the segments to the growth of the chronic myelogenous leukemia therapeutics market size.
With a complete study of the growth opportunities for companies, it has been identified that North America will account for the highest share of the chronic myelogenous leukemia therapeutics market throughout the forecast period. Vendors operating in the region are providing patient-assistance programs, such as co-pay assistance and free trial programs to reduce patients’ burden. These patient-assistance programs are also inclusive of reimbursement support, financial co-payment assistance, medication adherence, and supportive care. Such initiatives by vendors are fueling the chronic myelogenous leukemia therapeutics market growth in North America.
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
PART 04: MARKET SIZING
PART 05: FIVE FORCES ANALYSIS
PART 06: MARKET SEGMENTATION BY PRODUCT
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
PART 09: DRIVERS AND CHALLENGES
PART 10: MARKET TRENDS
PART 11: VENDOR LANDSCAPE
PART 12: VENDOR ANALYSIS
PART 13: APPENDIX
PART 14: EXPLORE TECHNAVIO
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.